# Annie Lamont

> Annie Lamont is a Series A investor at Oak HC/FT (New York) backing Health Care and Medical. See 31 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Oak HC/FT](https://shizune.co/investors/profile/oak-hc-ft-partners)
- Location: New York, United States
- Total investments: 31
- Last investment: Jul 2026
- Lead investor: 55%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/annielamont/
- X (Twitter): https://twitter.com/annielamont
- Website: https://x.com/annielamont

Annie Lamont is a Series A investor at Oak HC/FT in New York focused on Health Care and Medical. Annie Lamont is based out of Stamford, Connecticut, the Co-Founder and Managing Partner at Oak HC/FT. Annie previously worked as a Managing Partner at Oak Investment Partners. Annie Lamont attended Stanford University. Annie Lamont has received 100 Most Influential Women in U.S. Finance award.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 12 | 39% |
| Medical | 4 | 13% |
| Artificial Intelligence | 4 | 13% |
| FinTech | 3 | 10% |
| Home Health Care | 3 | 10% |

35 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 8 | 26% |
| Series C | 7 | 23% |
| Series B | 4 | 13% |
| Series D | 2 | 6% |
| Funding Round | 2 | 6% |

9 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 15 | 48% |
| Canada | 2 | 6% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Chai Discovery | Chai Discovery creates Chai-1, a multi-modal foundation model designed for predicting molecular structures relevant to drug discovery. The model facilitates the unified prediction of proteins, small molecules, and nucleic acids, and is available for free for commercial applications. By enabling accurate predictions without the need for multiplesequence alignments, Chai-1 advances the capabilities of molecular modeling in the life sciences. | $400M | Series C | Jul 14, 2026 |  |
| Corner Health | Operator of a nurse practitioner management platform intended to empower nurses to start and manage their independent practices. | $25M | Series A | Jul 13, 2026 |  |
| Fundamental | Fundamental is an AI research company that focuses on overcoming the fundamental challenges of machine learning in large-scale tabular systems. | $225M | Series A | Feb 05, 2026 |  |
| Chai Discovery | Chai Discovery creates Chai-1, a multi-modal foundation model designed for predicting molecular structures relevant to drug discovery. The model facilitates the unified prediction of proteins, small molecules, and nucleic acids, and is available for free for commercial applications. By enabling accurate predictions without the need for multiplesequence alignments, Chai-1 advances the capabilities of molecular modeling in the life sciences. | $130M | Series B | Dec 15, 2025 |  |
| Vesta Healthcare | Vesta Healthcare is an industry-leading technology and clinical services organization, dedicated to connecting caregiver insights to the rest of the care team. Vesta Healthcare proactively identifies the need for additional resources in the home and provides 24/7 telehealth support for caregivers and care recipients, with a focus on high-need,frail senior populations. Vesta partners with home care agencies, health plans and providers to create value-based population health programs that emphasize clinical quality, improved health outcomes and personalized engagement. Vesta Healthcare is headquartered in New York, NY. | $55M | Series C | Mar 13, 2024 |  |
| Main Street Health | Main Street Health is a provider of value-based, care-focused healthcare services aimed at addressing rural wellness concerns. The company's healthcare services are data-driven, and it provides partner clinics with employees, technology, critical access hospitals, community health centers, and possibilities to flourish in the care deliverymodel, allowing rural residents to receive the high-quality treatment they need. |  | Series B | Oct 08, 2023 |  |
| Main Street Health | Main Street Health is a provider of value-based, care-focused healthcare services aimed at addressing rural wellness concerns. The company's healthcare services are data-driven, and it provides partner clinics with employees, technology, critical access hospitals, community health centers, and possibilities to flourish in the care deliverymodel, allowing rural residents to receive the high-quality treatment they need. | $315M | Venture - Series Unknown | Oct 08, 2023 |  |
| Pagaya | Pagaya Investments (Pagaya) is a financial technology company reshaping the asset management space using machine learning and big data analytics to manage institutional money. With a focus on fixed income and alternative credit, Pagaya offers a variety of discretionary funds to institutional investors including pension funds, insurance companies,and banks. Pagaya’s unique technology platform — Pagaya Pulse — runs on a suite of artificial intelligence technologies and state-of-the-art algorithms to deliver a consistently high and scalable performance edge. The company was founded in 2016 by seasoned finance and technology professionals with offices in New York and Tel Aviv. | $75M | Post-IPO Equity | Apr 14, 2023 |  |
| Everside Health | Everside Health is a direct primary care provider offering convenient on-site, near-site, and virtual care for its members. Everside’s data-driven, patient-centric healthcare delivery model aligns incentives to benefit the patient, the physician, and the benefit provider, all while reducing the total cost of care.Everside Health was founded in2010 and is based in Denver, Colorado. | $164M | Venture - Series Unknown | Jul 25, 2022 |  |
| Everside Health | Everside Health is a direct primary care provider offering convenient on-site, near-site, and virtual care for its members. Everside’s data-driven, patient-centric healthcare delivery model aligns incentives to benefit the patient, the physician, and the benefit provider, all while reducing the total cost of care.Everside Health was founded in2010 and is based in Denver, Colorado. | $164M | Private Equity | Jul 25, 2022 |  |

10 of 31 investments shown.

## Co-investors
- [Optum Ventures](https://shizune.co/investors/profile/optum-ventures) — VC Fund, 7 deals together
- [Generator Ventures](https://shizune.co/investors/profile/generator-ventures) — VC Fund, 4 deals together
- [Google Ventures](https://shizune.co/investors/profile/google-ventures) — VC Fund, 4 deals together
- [Lux Capital](https://shizune.co/investors/profile/lux-capital) — VC Fund, 4 deals together
- [Alta Partners](https://shizune.co/investors/profile/alta-partners) — VC Fund, 3 deals together
- [Blue Cross Blue Shield of Massachusetts](https://shizune.co/investors/profile/blue-cross-blue-shield-of-massachusetts) — VC Fund, 3 deals together

## About Oak HC/FT

VC Fund · Greenwich, United States

Oak HC/FT is a venture and growth equity investment firm that focuses on healthcare information services and financial service technology. The firm focuses on driving transformation in these industries by providing entrepreneurs and companies with strategic counsel, board-level participation, and access to our extensive network of industryleaders.Oak HC/FT partners are peerless in delivering returns for investors and growing innovative businesses. Over the past decade, the partners at Oak HC/FT have had 20 realizations with 6 companies achieving valuations in excess of $1 billion.Oak HC/FT is led by the Healthcare and FinTech team of Oak Investment Partners as part of Oak’s strategy to develop sector-specific funds and continue its legacy of building best-in-class businesses.

5 contacts available at Oak HC/FT.

| Name | Title | Profile |
| --- | --- | --- |
| Andrew Adams | Co-Founder & Managing Partner | https://shizune.co/investors/profile/andrew-adams |
| Annie Lamont | Co-Founder & Managing Partner | https://shizune.co/investors/profile/annie-lamont |
| Billy Deitch | Partner | https://shizune.co/investors/profile/billy-deitch |
| Eliza Adams | Investor | https://shizune.co/investors/profile/eliza-adams |
| Michael Heller | Venture Partner | https://shizune.co/investors/profile/michael-heller-3 |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Annie Lamont invest in?

Annie Lamont invests primarily in Health Care, Medical and Artificial Intelligence startups, most often at Series A and Series C stage. Most of the 31 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Annie Lamont last invest?

The most recent investment recorded for Annie Lamont closed in Jul 2026. Shizune tracks 31 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co